Aim Immunotech INC Form 4 insider transactions

AIM ImmunoTech's CEO, Thomas K. Equels, converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock.

AIM ImmunoTech Director David I. Chemerow converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock.

AIM ImmunoTech Inc. Director David I. Chemerow has filed a Form 4 indicating a planned acquisition of 2,800 common shares on February 5, 2026, through a trust.

AIM ImmunoTech Director and 10% Owner Ted D. Kellner has filed a Form 4 disclosing a planned transfer of his directly held shares to Kelvest I LP, effective July 17, 2025, under a Rule 10b5-1 plan.

AIM ImmunoTech Inc.'s CEO and President, Thomas K. Equels, acquired 107 shares of common stock at $7.697 per share, increasing his direct beneficial ownership to 38,885 shares.

AIM ImmunoTech Inc.'s CEO and President, Thomas K Equels, has reported the direct acquisition of 103 shares of common stock at a price of $8.70 per share, increasing his total direct beneficial ownership to 38,675 shares.

Director William M Mitchell reports acquisition of AIM ImmunoTech shares following NYSE American approval.

AIM ImmunoTech's CEO and President, Thomas K. Equels, reports the acquisition of 1,968,504 shares of common stock at $0.0254 per share.

Director Ted Kellner reports acquisition of AIM ImmunoTech shares through direct purchase and indirect holdings via various entities.

AIM ImmunoTech's CEO, Thomas K Equels, purchased 41,000 shares of common stock at $0.063 per share on April 4, 2025.

Peter W. Rodino III, COO, Secretary, and General Counsel of AIM ImmunoTech Inc., purchased 500 shares of common stock at $0.087 per share on April 4, 2025.

Director William M. Mitchell acquired 44,899 shares of AIM ImmunoTech Inc. common stock in lieu of director compensation under the company's Cash Conservation Plan.

Director Nancy Bryan acquired 44,899 shares of AIM ImmunoTech Inc. common stock on March 14, 2025, in lieu of cash compensation under the company's Cash Conservation Plan.

David I. Chemerow, a director of AIM ImmunoTech Inc., acquired 44,899 shares of common stock in lieu of cash compensation on March 14, 2025.

AIM ImmunoTech CEO Thomas Equels reports purchasing 50,000 shares of common stock at $0.1346 per share, increasing his total holdings to 1,858,029 shares.

AIM ImmunoTech CEO Thomas Equels acquired 44,000 shares of common stock at $0.115 per share, increasing his direct holdings to 1,808,029 shares.

David Chemerow, a director at AIM ImmunoTech Inc., acquired 19,290 shares of common stock in lieu of cash compensation on February 28, 2025.

Director William M Mitchell acquires 38,580 shares of AIM ImmunoTech Inc. in lieu of cash compensation under the company's Cash Conservation Plan.

Director Nancy Bryan acquired 38,580 shares of AIM ImmunoTech Inc. common stock on February 28, 2025, in lieu of cash compensation under the company's Cash Conservation Plan.

Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., purchased 83,334 shares of common stock at $0.12 per share on March 4, 2025.

William M Mitchell, a director at AIM ImmunoTech Inc., acquired 27,412 shares of common stock in lieu of director compensation.

Director William M Mitchell acquires 43,330 shares of AIM ImmunoTech Inc. in lieu of director compensation.

Director William M Mitchell acquires shares of AIM ImmunoTech Inc. in lieu of director compensation, according to a Form 4/A filing.

Director William M. Mitchell acquired 43,330 shares of AIM ImmunoTech Inc. common stock in lieu of cash compensation under the company's Cash Conservation Plan.

Director Nancy Bryan acquired 43,330 shares of AIM ImmunoTech Inc. common stock on February 14, 2025, in lieu of director compensation.

William M. Mitchell, a director at AIM ImmunoTech Inc., disposed of shares acquired as compensation under the company's Cash Conservation Plan.

Director Nancy Bryan acquired 25,797 shares of AIM ImmunoTech Inc. common stock on January 31, 2025, in lieu of cash compensation under the company's Cash Conservation Plan.

AIM ImmunoTech CEO Thomas K. Equels purchased 20,000 shares of common stock at a price of $0.212 per share on November 21, 2024.

Nancy Bryan, a director at AIM ImmunoTech Inc., acquired 27,412 shares of common stock on January 15, 2025, in lieu of cash compensation under the company's Cash Conservation Plan.

Director William M. Mitchell acquires shares of AIM ImmunoTech Inc. in lieu of director compensation.